Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections

International Journal of Artificial Organs

Volumn 32, Issue 9, 2009, Pages 635-641

  Arciola, Carla Renata ^a,b   Speziale, Pietro ^c   Montanaro, Lucio ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adhesins; DNA vaccines; Implant infections; MSCRAMMs; Staphylococcus aureus

Indexed keywords

ANTIGENS; DNA; IMMUNE SYSTEM; VACCINES;

ADHESIN; ANTIGEN PRESENTATION; ANTIGEN PROCESSING; DNA VACCINE; IMMUNE RESPONSE; IMPLANT INFECTIONS; INFECTIOUS PATHOGENS; MSCRAMM; PLASMID DNA; VIRULENCE FACTORS;

BACTERIA;

ADHESIN; BIOMATERIAL; DNA VACCINE; FIBRONECTIN BINDING PROTEIN; PLASMID DNA; SCLEROPROTEIN; SORTASE; STAPHYLOCOCCUS VACCINE;

ANTIGENIC VARIATION; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PROSTHESIS INFECTION; PROTEIN PURIFICATION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 70549084723     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200913     Document Type: Review

References (70)

1. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9: 776-88.
2. Smith HA. Regulation and review of DNA vaccine products. Dev Biol (Basel) 2000; 104: 57-62.
3. Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol 1999; 42: 343-410.
4. Tang D, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
5. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008; 4: 453-6.
6. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002; 76: 6652-9.
7. Applequist SE, Rollman E, Wareing MD, et al. Activation of innate immunity, inflammation and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005; 175: 3882-91.
8. Saha S, Takeshita F, Matsuda T, et al. Blocking of the TLR5 Activation Domain Hampers Protective Potential of Flagellin DNA Vaccine. J Immunol 2007; 179: 1147-54.
9. Stevenson FK. DNA vaccines and adjuvants. Immunol Rev 2004; 199: 5-8.
10. Laddy DJ and Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25: 99-123.
11. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
12. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007; 6: 797-808.
13. Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008; 6: 4.
14. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000; 18: 927-74.
15. Klinman DM, Ishii KJ, Verthelyi D. CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr Top Microbiol Immunol 2000; 247:131-42.
16. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006; 24: 5110-8.
17. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
18. Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. Etiology of implant orthopedic infections: a survey on 1027 clinical isolates. Int J Artif Organs 2005; 28: 1091-100.
19. Patti JM, Allen BL, McGavin MJ, Höök M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994; 48: 585-617.
20. Signas C, Raucci G, Jonsson K, et al. Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci U S A 1989; 86: 699-703.
21. Jonsson K, Signas C, Muller HP, Lindberg M. Two different genes encode fibronectin binding proteins in Staphylococcus aureus. The complete nucleotide sequence and characterization of the second gene. Eur J Biochem 1991; 202: 1041-8.
22. Peacock SJ, Day NP, Thomas MG, Berendt AR, Foster TJ. Clinical isolates of Staphylococcus aureus exhibit diversity in fnb genes and adhesion to human fibronectin. J Infect 2000; 41: 23-31.
23. Roche FM, Downer R, Keane F, Speziale P, Park PW, Foster TJ. The N-terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin. J Biol Chem 2004; 279: 38433-40.
24. Wann ER, Gurusiddappa S, Hook M. The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J Biol Chem 2000; 275: 13863-71.
25. Wann ER, Gurusiddappa S, Hook M. The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J Biol Chem 2000; 275: 13863-71.
26. Meenan NA, Visai L, Valtulina V, et al. The tandem beta-zipper model defines high affinity fibronectin-binding repeats within Staphylococcus aureus FnBPA. J Biol Chem 2007; 282: 25893-902.
27. Sinha B, Francois PP, Nusse O, et al. Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol 1999; 1: 101-17.
28. Massey RC, Kantzanou MN, Fowler T, et al. Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol 2001; 3: 839-51.
29. Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 2006; 59: 212-30.
30. Heilmann C, Niemann S, Sinha B, Herrmann M, Kehrel BE, Peters G. Staphylococcus aureus fibronectin-binding protein (FnBP)-mediated adherence to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. J Infect Dis 2004; 190: 321-9.
31. Applequist SE, Rollman E, Wareing MD, et al. Activation of innate immunity, inflammation and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005; 175: 3882-91.
32. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002; 76: 6652-9.
33. Keane FM, Loughman A, Valtulina V, Brennan M, Speziale P, Foster TJ. Fibrinogen and elastin bind to the same region within the A domain of fibronectin binding protein A, an MSCRAMM of Staphylococcus aureus. Mol Microbiol 2007; 63: 711-23.
34. Loughman A, Sweeney T, Keane FM, Pietrocola G, Speziale P, Foster TJ. Sequence diversity in the A domain of Staphylococcus aureus fibronectin-binding protein A. BMC Microbiology 2008; 8: 74.
35. Xu Y, Rivas JM, Brown EL, Liang X, Höök MJ. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis 2004; 189: 2323-33.
36. Zong Y, Xu Y, Liang X, Keene DR, et al. A 'Collagen Hug' model for Staphylococcus aureus CNA binding to collagen. EMBO J 2005; 24: 4224-36.
37. McDevitt D Francois P, Vaudaux P, Foster TJ. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 1994; 11: 237-248.
38. Ní Eidhin D, Perkins S, Francois P, Vaudaux P, Höök M, Foster TJ. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol 1998; 30: 245-57.
39. McDevitt D, McDevitt D, Nanavaty T, et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997; 247: 416-24.
40. Walsh EJ, Miajlovic H, Gorkun OV, Foster TJ. Identification of the Staphylococcus aureus MSCRAMM clumping factor B (ClfB) binding site in the alpha C-domain of human fibrinogen. Microbiology 2008; 156 (Pt. 2): 550-8.
41. Loughman A, Fitzgerald JR, Brennan MP, et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57: 804-18.
42. Miajlovic H, Loughman A, Brennan M, Cox D, Foster TJ. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B. Infect Immun 2007; 75: 3335-43.
43. O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 2002; 4: 759-770. 44 Corrigan RM, Miajlovic H, Foster TJ. Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiol 2009; 9: 22.
44. Rivas JM, Speziale P, Patti JM, Höök M. MSCRAMM - targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Discov Devel 2004; 7: 223-7.
45. Patti JM. Vaccines and immunotherapy for staphylococcal infections. Int J Artif Organs 2005; 28: 1157-62.
46. Patti JM, Boles JO, Höök M. Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus. Biochemistry 1993; 32: 11428-35.
47. Hienz SA, Schennings T, Heimdahl A, Flock JI: Collagen binding of Staphylococcus aureus is a virulence factor in experimental endocarditis. J Infect Dis 1996; 174: 83-88.
48. Montanaro L, Arciola CR, Baldassarri L, Borsetti E. Presence and expression of collagen adhesin gene (cna) and slime production in Staphylococcus aureus strains from orthopaedic prosthesis infections. Biomaterials 1999; 20: 1945-9.
49. Rhem MN, Lech EM, Patti JM, et al. The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitis. Infect Immun 2000; 68: 3776-9.
50. Elasri MO, Thomas JR, Skinner RA et al. Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone 2002; 30: 275-80.
51. Xu Y, Rivas JM, Brown EL, Liang X, Höök MJ. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis 2004; 189: 2323-33.
52. Arciola CR, Campoccia D, Gamberini S, Baldassarri L, Montanaro L. Prevalence of cna, fnbA and fnbB adhesin genes among Staphylococcus aureus isolates from orthopedic infections associated to different types of implant. FEMS Microbiol Lett 2005; 246: 81-6.
53. Therrien R, Lacasse P, Grondin G, Talbot BG. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 2007; 25: 5053-61.
54. Brouillette E, Lacasse P, Shkreta L, et al. DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 2002; 20: 2348-57.
55. Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus 2007; 25: 814-24.
56. Castagliuolo I, Piccinini R, Beggiao E Palù G, Mengoli C, Ditadi F, Vicenzoni G, Zecconi A. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice. Vaccine 2006; 24: 4393-402.
57. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. PNAS 2006; 103: 16942-7.
58. Piroth L, Que YA, Widmer E, et al. The fibrinogen- and fibronectin-binding domains of Staphylococcus aureus fibronectin-binding protein A synergistically promote endothelial invasion and experimental endocarditis. Infect Immun 2008; 76: 3824-31.
59. Margarit I, Bonacci S, Pietrocola G, et al. Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. FASEB J 2009 May 5.
60. Montanaro L, Campoccia D, Arciola CR. Biomaterials. Advancements in molecular epidemiology of implant infections and future perspectives. Biomaterials 2007; 28: 5155-68.
61. Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today 2009; 14: 252-60. 63 Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs 2005; 28: 1062-8.
62. Arciola CR, Baldassarri L, Von Eiff C, et al. Prevalence of genes encoding for staphylococcal leukocidal toxins among clinical isolates of Staphylococcus aureus from implant orthopedic infections. Int J Artif Organs 2007; 30: 792-7.
63. Mack D, Rohde H, Harris LG, Davies AP, Horstkotte MA, Knobloch JK. Biofilm formation in medical device-related infection. Int J Artif Organs 2006; 29: 343-59.
64. Arciola CR, Alvi FI, An YH, Campoccia D, Montanaro L. Implant infection and infection resistant materials: a mini review. Int J Artif Organs 2005; 28: 1119-25.
65. Vadyvaloo V, Otto M. Molecular genetics of Staphylococcus epidermidis biofilms on indwelling medical devices. Int J Artif Organs 2005; 28: 1069-78.
66. Verran J, Whitehead K. Factors affecting microbial adhesion to stainless steel and other materials used in medical devices. Int J Artif Organs 2005; 28: 1138-45.
67. Campoccia D, Baldassarri L, Pirini V, Ravaioli S, Montanaro L, Arciola CR. Molecular epidemiology of Staphylococcus aureus from implant orthopaedic infections: ribotypes, agr polymorphism, leukocidal toxins and antibiotic resistance. Biomaterials 2008; 29: 4108-16.
68. Arciola CR, Bustanji Y, Conti M, Campoccia D, Baldassarri L, Samorì B, Montanaro L. Staphylococcus epidermidis-fibronectin binding and its inhibition by heparin. Biomaterials 2003; 24: 3013-9..
69. Bustanji Y, Arciola CR, Conti M, Mandello E, Montanaro L, Samorí B. Dynamics of the interaction between a fibronectin molecule and a living bacterium under mechanical force. Proc Natl Acad Sci U S A. 2003; 100: 13292-7.
70. Song R, Liu S, Adams RJ, Leong KW. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. J Interferon Cytokine Res 2006; 26: 380-9.